GE Healthcare, CCRM, Sartorius Stedim Biotech (formerly TAP Biosystems), Lonza, CIRM, SENS Research Foundation, UK Cell Therapy Catapult, NIH Centre for Regenerative Medicine, NYSCF, ThermoFisher Scientific, Eisai, Medipost (US), Medipost (Korea), Celgene, Roche, Oxford Biomedica, Oxford NIHR BRU, the Saïd Foundation, the SENS Research Foundation, Innovate UK (formerly Technology Strategy Board).
DPhil MEng RAC (US) PGCert IP FRSA FRSB
Senior Research Fellow in Healthcare Translation
Dr David Brindley leads the Healthcare Translation Group in the Department of Paediatrics at the University of Oxford, which specialises in the evaluation and development of processes impacting the translation of scientific innovations into clinical and commercial outcomes. The group researches and develops novel therapeutic and diagnostic platforms. It also works in the complementary field of digital health technologies which are utilised to support the rapid deployment of the above platforms.
Supported by international philanthropic and industrial funders and research bodies, the Healthcare Translation Group undertakes interdisciplinary research delivering real-world impact in regenerative medicine (cell, gene, immuno-therapies and tissue engineering), vaccines, gene editing technologies and digital health – this includes medicines optimisation and supply chain security.
David has published over 90 peer reviewed publications in high impact journals including Nature, Cell Stem Cell, Nature Medicine and Nature Biotechnology, and more than 10 book chapters, including a number in the RAPS Fundamentals of Regulatory Affairs (US and EU) series, the core text for the Regulatory Affairs Certificate (RAC) exam.
David originally trained as a Bioprocess Engineer, but he has subsequently added to this training and his expertise spans basic stem cell biology, drug development, clinical trial design, regulatory science, intellectual property and venture financing. This interdisciplinary approach to healthcare translation is shared by group members.
David completed his undergraduate studies in Biochemical Engineering at University College London with First Class Honours (Prof Chris Mason and Dr Ivan Wall), Masters jointly at the Harvard Stem Cell Institute and Harvard Business School (Mr Brock Reeve and Prof William Sahlman), and DPhil (PhD) in the risk:benefit appraisal of healthcare innovations at the University of Oxford (Worcester College – Profs Sir John Bell and Andrew Carr). His post-doctoral experience includes the role of Cooksey-Botnar-Saïd Fellow, the first joint post between the University of Oxford’s Medical Sciences Division and Saïd Business School. David holds the Regulatory Affairs Certificate (RAC, US), Chartered Alternative Investment Analyst (CAIA) Level 1, and postgraduate qualifications in intellectual property (PGCertIP).
Other research activities include collaborations at the Harvard Stem Cell Institute, Harvard Business School, University College London, Centre for Behavioural Medicine, the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovations (CASMI) and the Stanford-USCF FDA Centre for Regulatory Innovation and Science (CERSI).
David divides his time between academia and industry so as to maximise the commercial and patient impact of his research. Current and former roles include Chief Scientific Officer and Chief Operations Officer of therapeutic, diagnostic and digital health companies in Europe and North America. David is also an advisor to major biopharmaceutical companies, life science venture capital funds, healthcare orientated philanthropic organisations and international regulators, with particular expertise in the governance of GxP-regulated organisations.